Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
Study to evaluate the safety and tolerability of single ascending doses and multiple
 ascending doses of VX-509 administered to healthy male and female subjects
Part A of the study will evaluate the safety and tolerability, PK, and PD of single ascending
 doses of VX-509.

 Part B will evaluate the safety and tolerability, PK, and PD of multiple ascending doses of
 VX-509 administered for 14 days.

 A total of 72 subjects will be enrolled: 36 subjects in Part A and 36 subjects in Part B.
Inclusion Criteria:

 -  Healthy, non-smoking male or healthy, non-smoking, non-pregnant female

 -  Able to comply with study procedures

 -  Male subjects must agree to use 2 highly effective methods of contraception

 -  Female subjects must be of documented non-child-bearing potential or must agree to use
 2 highly effective methods of contraception

 -  No clinically significant abnormal results for physical examination or clinically
 significant out of range laboratory results

 Exclusion Criteria:

 -  History of any significant illness

 -  Illness within 5 days before Day 1

 -  Regular treatment with any medications

 -  Any type of tobacco or nicotine use

 -  History of drug or alcohol abuse or addiction within 2 years before Screening visit

 -  Positive tuberculin skin test at Screening

 -  Female subjects who are lactating or planning to become pregnant during the study
 period or within 90 days of last dose of study drug